Pharmacogenetics for off-patent antipsychotics: Reframing the risk for tardive dyskinesia and access to essential medicines

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 2, 2006, Pages 119-133

  Ozdemir, Vural ^a,b   Aklillu, Eleni ^c   Mee, Steven ^a   Bertilsson, Leif ^c   Albers, Lawrence J ^a   Graham, Janice E ^d   Caligiuri, Michael ^b,e   Lohr, James B ^b,e   Reist, Christopher ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; Bioethics; Biomarker; CYP1A2; CYP2D6; DRD3; Essential medicines policy; HTR2A; Pharmacogenetics; Tardive dyskinesia; World Health Organization

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHLORPROMAZINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DRUG METABOLIZING ENZYME; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

CHOREOATHETOSIS; CLINICAL TRIAL; DATA BASE; DECISION MAKING; DISABILITY; DISTRESS SYNDROME; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSKINESIA; ETHNOLOGY; FACE MUSCLE; GENETIC ASSOCIATION; HEALTH CARE ACCESS; HEALTH ECONOMICS; HUMAN; HYPERKINESIA; LONG TERM CARE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATENT; PATHOGENESIS; PHARMACOGENETICS; PREDICTION; PSYCHOSIS; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; TARDIVE DYSKINESIA; TONGUE DISEASE; WORLD HEALTH ORGANIZATION;

EID: 33144468024     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.2.119     Document Type: Review

References (84)

1. TAMMINGA CA, WOERNER MG: Clinical course and cellular pathology of tardive dyskinesia. In: Neuropsychopharmacology: the fifth generation of progress. Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), American College of Neuropsychoparmacology, Lippincott Williams & Wilkins, Philadelphia, (2002): 1831-1841.
2. KANE JM, WOERNER M, WEINHOLD P et al.: Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol. Bull. (1984) 20:39-40.
3. LOHR JB, BRAFF DL: The value of referring to recently introduced antipsychotics as 'second generation'. Am. J. Psychiatry (2003) 160:1371-1372.
4. MARDER SR, ESSOCK SM, MILLER AL et al.: The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. (2002) 28:5-16.
5. LOHR JB, KUCZENSKI R, NICULESCU AB: Oxidative mechanisms and tardive dyskinesia. CNS Drugs (2003) 17:47-62.
6. REIST C, ALBERS LJ, MINTZ J, SZABO S, JAMAL MM, OZDEMIR V: Second-generation antipsychotic exposure and patterns of change in metabolic related disorders in patients with schizophrenia: a longitudinal pharmacoepidemiology study from 1988 to 2002. Neuropsychopharmacology (2005) 30:S249-S250.
7. CALIGIURI MP, JESTE DV: Association of diabetes with dyskinesia in older psychosis patients. Pychopharmacology (2004) 176:281-286.
8. LOHR JB, CALIGIURI MP, EDSON R et al.: Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394. J. Clin. Pychopharmacol. (2002) 22:196-200.
9. CALIGIURI MP, JESTE DV, LACRO JP: Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging (2000) 17:363-384.
10. CASEY DE: Tardive dyskinesia and atypical antipsychotic drugs. Schizophr. Res. (1999) 35(Suppl.):S61-S66.
11. ALBERS LJ, OZDEMIR V: Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr. Med. Chem. (2004) 11:297-312.
12. REIST C, ALBERS LJ, MARDER SR et al.: A candidate pathway strategy for integration of pharmacogenomic components of variability in antipsychotic treatment outcomes: a focus on aripiprazole. Curr. Pharmacogenomics (2005) 3:305-317.
13. BIOMARKERS DEFINITIONS WORKING GROUP: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. (2001) 69:89-95.
14. WEINHOLD P, WEGNER JT, KANE JM: Familial occurrence of tardive dyskinesia. J. Clin. Psychiatry (1981) 42:165-166.
15. OZDEMIR V, KALOW W, TOTHFALUSI L, BERTILSSON L, ENDRENYI L, GRAHAM JE: Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr. Pharmacogenomics (2005) 3:53-71.
16. MALHOTRA AK: From pharmacogenetics to pharmacogenomics of psychotropic drug response. In: Pharmacogenetics of Psychotropic Drugs. Lerer B (Ed.), Cambridge University Press: Cambridge, UK (2002):21-35.
17. SEGMAN RH, LERER B: Genetic factors underlying drug induced tardive dyskinesia. In: Pharmacogenetics of Psychotropic Drugs. Lerer B (Ed.), Cambridge University, Cambridge, UK (2002).
18. BERTILSSON L, DAHL ML, DALEN P, AL-SHURBAJI A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. (2002) 53:111-122.
19. JOHANSSON I, LUNDQVIST E, BERTILSSON L, DAHL ML, SJÖQVIST F, INGELMAN-SUNDBERG M: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA (1993) 90:11825-11829.
20. AKLILLU E, PERSSON I, BERTILSSON L, JOHANSSON I, RODRIGUES F, INGELMAN-SUNDBERG M: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. (1996) 278:441-446.
21. BERTILSSON L, DAHL ML, SJÖQVIST F et al.: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 341:63.
22. DORADO P, CACERES MC, POZO-GUISADO E, WONG ML, LICINIO J, LLERENA A: Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques (2005) 39:571-574.
23. BROCKMOLLER J, KIRCHHEINER J, SCHMIDER J et al.: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. (2002) 72:438-452.
24. ARTHUR H, DAHL ML, SIWERS B, SJÖQVIST F: Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. (1995) 15:211-216.
25. KAPITANY T, MESZAROS K, LENZINGER E et al.: Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res. (1998) 32:101-106.
26. JAANSON P, MARANDI T, KIIVET RA et al.: Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (2002) 162:67-73.
27. ANDREASSEN OA, MACEWAN T, GULBRANDSEN AK, MCCREADIE RG, STEEN VM: Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Pychopharmacology (1997) 131:174-179.
28. PATSOPOULOS NA, NTZANI EE, ZINTZARAS E, IOANNIDIS JP: CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet. Genomics (2005) 15:151-158.
29. OHMORI O, KOJIMA H, SHINKAI T, TERAO T, SUZUKI T, ABE K: Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res. (1999) 87:239-244.
30. AKLILLU E, HERRLIN K, GUSTAFSSON LL, BERTILSSON L, INGELMAN-SUNDBERG M: Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics (2002) 12:375-383.
31. OHMORI O, SUZUKI T, KOJIMA H et al.: Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res. (1998) 32:107-113.
32. LIOU YJ, WANG YC, BAI YM et al.: Cytochrome P450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology (2004) 49:167-173.
33. LAM LC, GARCIA-BARCELO MM, UNGVARI GS et al.: Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry (2001) 34:238-241.
34. KAWANISHI C, LUNDGREN S, AGREN H, BERTILSSON L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. (2004) 59:803-807.
35. BERTILSSON L, CARRILLO JA, DAHL ML et al.: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. (1994) 38:471-473.
36. CARRILLO JA, HERRAIZ AG, RAMOS SI et al.: Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J. Clin. Psychopharmacol. (2003) 23:119-127.
37. LOHR JB, FLYNN K: Smoking and schizophrenia. Schizophr. Res. (1992) 8:93-102.
38. BASILE VS, OZDEMIR V, MASELLIS M et al.: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry (2000) 5:410-417.
39. SCHULZE TG, SCHUMACHER J, MULLER DJ et al.: Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. (2001) 105:498-501.
40. CHONG SA, TAN EC, TAN CH, MYTHILY: Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J. Psychiatry Neurosci. (2003) 28:185-189.
41. MATSUMOTO C, OHMORI O, SHINKAI T, HORI H, NAKAMURA J: Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Pychiatr. Genet. (2004) 14:209-213.
42. TIWARI AK, DESHPANDE SN, RAO AR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. (2005) 5:60-69.
43. AKLILLU E, CARRILLO JA, MAKONNEN E et al.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. (2003) 64:659-669.
44. SCORDO MG, SPINA E, ROMEO P et al.: CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur. J. Clin. Pharmacol. (2000) 56:679-683.
45. LOHMANN PL, BAGLI M, KRAUSS H et al.: CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry (2003) 36:73-78.
46. NIKOLOFF D, SHIM JC, FAIRCHILD M et al.: Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J. (2002) 2:400-407.
47. CALIGIURI MP, BUITENHUYS C: Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype? Neuropsychopharmacology (2005) 30(12):2125-2134.
48. LERER B, SEGMAN RH, FANGERAU H et al.: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 27:105-119.
49. LERER B, SEGMAN RH, TAN EC, et al.: Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int. J. Neuropsychopharmacol. (2005) 8:411-425.
50. STEEN VM, LOVLIE R, MACEWAN T, MCCREADIE RG: Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry (1997) 2:139-145.
51. BASILE VS, MASELLIS M, BADRI F et al.: Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology (1999) 21:17-27.
52. SEGMAN R, NEEMAN T, HERESCO-LEVY U et al.: Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry (1999) 4:247-253.
53. KAPUR S, REMINGTON G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry (1996) 153:466-476.
54. POLESSKAYA OO, SOKOLOV BP: Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. (2002) 67:812-822.
55. BRAY NJ, BUCKLAND PR, HALL H, OWEN MJ, O'DONOVAN MC: The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol. Psychiatry (2004) 9:109-114.
56. TURECKI G, BRIERE R, DEWAR K et al.: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Pychiatry (1999) 156:1456-1458.
57. KOUZMENKO AP, SCAFFIDI A, PEREIRA AM, HAYES WL, COPOLOV DL, DEAN B: No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum. Hered. (1999) 49:103-105.
58. PARSONS MJ, D'SOUZA UM, ARRANZ MJ, KERWIN RW, MAKOFF AJ: (2004) The -1438A/G polymorphism in the 5-hydroxytryptamine Type 2A receptor gene affects promoter activity. Biol. Psychiatry (2004) 56:406-410.
59. OZAKI N, MANJI H, LUBIERMAN V et al.: A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J. Neurochem. (1997) 68:2186-2193.
60. MULLER DJ, SHINKAI T, DE LUCA V, KENNEDY JL: Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J. (2004) 4:77-87.
61. JESTE DV: Tardive dyskinesia in older patients. J. Clin. Psychiatry (2000) 61:27-32.
62. CADET JL, LOHR JB: Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann. N. Y. Acad. Sci. (1989) 570:176-185.
63. FOURIE J, OLESCHUK CJ, GUZIEC F et al.: The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother. Pharmacol. (2002) 49:101-110.
64. SADEE W, HOEG E, LUCAS J, WANG D: Genetic variations in human G protein-couplcd receptors: implications for drug therapy. AAPS Pharm Sci. (2001) 3:E22.
65. FOURIE J, DIASIO R: Pharmacogenetics. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th edn. Chabner BA, Longo DL. (Eds), Lippincott Williams and Wilkins Co., Philadelphia, (2005):529-548.
66. QUICK JD: Ensuring access to essential medicines in the developing countries: a framework for action. Clin. Pharmacol. Ther. (2003) 73:279-283.
67. LEVY M, REIDENBERG MM: What has been the impact of the concept of essential drugs? Clin. Pharmacol. Ther. (2003) 73:275-278.
68. HOGERZEIL HV: The concept of essential medicines: lessons for rich countries. Br. Med. J. (2004) 329:1169-1172.
69. ROSENHECK R, PERLICK D, BINGHAM S et al.: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA (2003) 290(20):2693-2702.
70. WILLLAMS-JONES B, GRAHAM JE: Actor-network theory: a tool to support ethical analysis of commercial genetic testing. New Genetics and Society (2003) 22:271-296.
71. HEDGECOE AM: Terminology and the construction of scientific disciplines: the case of pharmacogenomics. Science, Technology and Human Values (2003) 28:513-537.
72. CORRIGAN OP: Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. J. Med. Ethics (2005) 31:144-148.
73. DWYER J: Global health and justice. Bioethics (2005) 19:460-475.
74. SMART A, MARTIN P, PARKER M: Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics, (2004) 18:322-342.
75. HEDGECOE A: The politics of personalised medicine - pharmacogenetics in the clinic. In: Cambridge Studies in Society and the Life Sciences. Cambridge University Press, Cambridge, UK (2004):1-208.
76. WILLIAMS-JONES B, CORRIGAN OP: Rhetoric and hype: where's the 'ethics' in pharmacogenomics? Am. J. Pharmacogenomics (2003) 3:375-383.
77. STEEN VM: Some new hope but still no hype for academic psychiatry in Norway. Mol. Psychiatry (2005) 10:127-128.
78. FRUEH FW, GOODSAID F, RUDMAN A, HUANG SM, LESKO LJ: The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J. (2005) 5:218-220.
79. KERWIN RW: A perspective on progress in pharmacogenomics. Am. J. Pharmacogenomics (2003) 3:371-373.
80. SEGMAN RH, GOLTSER-DUBNER T, MACCIARDI F, LERER B: A pharmacogenetic test for prediction of vulnerability to tardive dyskinesia. Neuropsychopharmacology (2005) 30:S252.
81. WILLIAMS-JONES B, OZDEMIR V: Enclosing the 'knowledge commons': patenting genes for disease risk and drug response at the university-industry interface. In: Ethics and Law of Intellectual Property. Current Problems in Politics, Science and Technology. Lenk C, Hoppe N, Andorno R (Eds), Ashgate Publishing, London (in press).
82. WILLIAMS-JONES B, OZDEMIR V: Apples and oranges? Patenting genes for disease risk and drug response. Canadian Bioethics Society Annual Meeting. Nova Scotia, Canada (20 - 23 October 2005)
83. DAY RO, BIRKETT DJ, MINERS J, SHENFIELD GM, HENRY DA, SEALE JP: Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology. A major theme of the 2004 World Congress of Clinical Pharmacology and Therapeutics was worldwide equity of access to medicines. Med. J. Aust. (2005) 182:322-323.
84. HEYMANN J, HERTZMAN C, BARER ML, EVANS RG. Healthier Societies. From Analysis to Action. (Eds.) Oxford University Press, Oxford, UK (2005).